Current - Issue

1. Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F. Spinal muscular atrophy — insights and challenges in the treatment era. Nat Rev
Dis Primers. 2022;8:52.
2. Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831–846.
3. Butchbach MER. Genomic variability in the survival motor neuron genes (SMN1 and SMN2): implications for spinal muscular atrophy
phenotype and therapeutics development. Int J Mol Sci. 2021;22(15):7896.
4. Spinal Muscular Atrophy. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. NCBI Bookshelf
ID: NBK1352.
5. Wirth B. Spinal muscular atrophy: molecular pathophysiology. Hum Genet. 2000.
6. Wishart TM, Mutsaers CA, Riessland M, Reimer MM, Hunter G, Hannam ML, et al. Dysregulation of ubiquitin homeostasis and β-
catenin signaling promote spinal muscular atrophy. J Clin Invest. 2014;124(4):1821–1834.
7. Powis RA, Karyka E, Boyd P, Côme J, Jones RA, Zheng Y, et al. Systemic restoration of UBA1 ameliorates disease in spinal muscular
atrophy. JCI Insight. 2016;1(11):e87908.
8. Ahmad S, Bhatia K, Kannan A, Gangwani L. Molecular mechanisms of neurodegeneration in spinal muscular atrophy. Neuroscientist.
2016;22(6):568–582.
9. Uzunallı G, Bora-Tatar G, Dayangaç-Erden D, Erdem-Yurter H. Effects of flavonoid quercetin on survival of motor neuron gene
expression. Cell Biol Int. 2015;39(3):350–354.
10. Qiao Y, Chi Y, Gu J, Ma Y. Safety and efficacy of nusinersen and risdiplam for spinal muscular atrophy: a systematic review and meta-
analysis of randomized controlled trials. Brain Sci. 2023;13(10):1419.
11. Crisafulli S, Boccanegra B, Vitturi G, Trifirò G, De Luca A. Pharmacological therapies of spinal muscular atrophy: a narrative review of
preclinical, clinical-experimental, and real-world evidence. Brain Sci. 2023;13(10):1446.
12. An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec, risdiplam or
combination therapies. 2024.
13. Systematic review of presymptomatic treatment for spinal muscular atrophy. 2024.14. Post-marketing safety of spinal muscular atrophy therapies: analysis of spontaneous adverse drug reactions from EudraVigilance. 2025.
15. Taldefgrobep alfa and the phase 3 RESILIENT trial in spinal muscular atrophy. 2024.
16. Targeting signaling pathways in neurodegenerative diseases: quercetin's cellular and molecular mechanisms for neuroprotection. 2025.
17. Bioactive effects of quercetin in the central nervous system: focusing on the mechanisms of actions. 2016.
18. Quercetin is an active agent in berries against neurodegenerative diseases progression through modulation of Nrf2/HO1. Nutrients. 2022.
19. New perspectives on the therapeutic potential of quercetin in non-communicable diseases: targeting Nrf2 to counteract oxidative stress
and inflammation. 2024.
20. Neuroprotective effect of quercetin and nano-quercetin against cyclophosphamide-induced oxidative stress in the rat brain: role of
Nrf2/HO-1/Keap-1 signaling pathway. 2023.
21. Park HJ, Kim HN, Kim CY, Seo MD, Baek SH. Synergistic protection by isoquercitrin and quercetin against glutamate-induced oxidative
cell death in HT22 cells via activating Nrf2 and HO-1 signaling pathway. Antioxidants (Basel). 2021;10(4):554.
22. Mechanistic insights and therapeutic potential of quercetin in neuroprotection: a comprehensive review of pathways and clinical
perspectives. Bio Integration. 2025.
23. Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism. 2022.
24. Guo H, et al. Quercetin induces pro-apoptotic autophagy via SIRT1/AMPK signaling pathway in human lung cancer cell lines A549 and
H1299 in vitro. Thorac Cancer. 2021.
25. Quercetin suppresses apoptosis and attenuates intervertebral disc degeneration via the SIRT1-autophagy pathway. Front Cell Dev Biol.
2020.
26. Feng K, et al. Quercetin attenuates mitochondrial dysfunction and biogenesis via upregulated AMPK/SIRT1 signaling pathway in
osteoarthritic rats. 2018.
27. Quercetin alleviates the accumulation of superoxide in sodium iodate-induced retinal autophagy by regulating mitochondrial reactive
oxygen species homeostasis through enhanced deacetyl-SOD2 via the Nrf2-PGC-1α-Sirt1 pathway. 2021.
28. Quercetin ameliorates oxidative stress-induced apoptosis of granulosa cells in dairy cow follicular cysts by activating autophagy via the
SIRT1/ROS/AMPK signaling pathway. 2024.
29. Dhawan S, Kapil R, Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved
brain delivery. J Pharm Pharmacol. 2011;63(3):342–351.
30. Oliveira AI, Pinho C, Sarmento B, et al. Quercetin–biapigenin nanoparticles are effective to penetrate the blood–brain barrier. Drug Deliv
Transl Res. 2022;12:267–281.
31. Investigating the impact of resveratrol and quercetin on glymphatic function, blood–brain barrier, and neuroglial health: a systematic
review. 2026.
32. Quercetin-functionalized nanomaterials: innovative therapeutic avenues for Alzheimer's disease management. 2025.
33. Using superparamagnetic iron oxide nanoparticles to enhance bioavailability of quercetin in the intact rat brain. 2018.
34. Recent advances in nanoformulations for quercetin delivery.
35. Pharmacokinetics and bioavailability of the flavonol quercetin in humans. 1999.
36. Quercetin as a therapeutic product: evaluation of its pharmacological action and clinical applications — a review. 2023.
37. Quercetin in metabolic diseases: mechanisms, therapeutics, and multidimensional frontiers. 2026.
38. Mahbub AA, et al. Quercetin protects against obesity-induced skeletal muscle inflammation and atrophy. 2015.
39. Liu Y, Wang D, Li T, Yang F, Li Z, Bai X, Wang Y. The role of NLRP3 inflammasome in inflammation-related skeletal muscle atrophy.
Front Immunol. 2022;13:1035709.